Isabel Teresa
Rubio
Consultora Médica
Fondazione IRCCS Istituto Nazionale dei Tumori
Milán, ItaliaPublikationen in Zusammenarbeit mit Forschern von Fondazione IRCCS Istituto Nazionale dei Tumori (6)
2021
-
Neoadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): a multicenter, two-cohort, non-randomized phase II trial
npj Breast Cancer, Vol. 7, Núm. 1
-
The ESSO core curriculum committee update on surgical oncology
European Journal of Surgical Oncology, Vol. 47, Núm. 11, pp. e1-e30
2016
-
Modeling anti-IL-6 therapy using breast cancer patient-derived xenografts
Oncotarget, Vol. 7, Núm. 42, pp. 67956-67965
2013
-
Factors associated with surgical management following neoadjuvant therapy in patients with primary HER2-positive breast cancer: Results from the NeoALTTO phase III trial
Annals of Oncology, Vol. 24, Núm. 8, pp. 1980-1985
-
Management of the axilla in early breast cancer patients in the genomic era
Annals of Oncology, Vol. 24, Núm. 5, pp. 1163-1170
-
Re: Time to adjuvant chemotherapy for breast cancer in national comprehensive cancer network institutions
Journal of the National Cancer Institute